Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-10-31

Clinical Trial Update: Mass Balance, Pharmacokinetics and Metabolism Study of Alisertib [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetics and metabolism study of alisertib completed; reports mass balance data in advanced solid tumors and lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Alisertib (alisertib)

Snippet

Sponsor: Millennium Pharmaceuticals, Inc. | Conditions: Advanced Solid Tumors, Lymphoma | Phase 1 | Status: COMPLETED | Results posted: 2018-10-31